- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lupin Limited reported strong Q2 FY2025 results with sales of INR 54,970 Mn, an 11.3% year-on-year increase, and a 73.5% rise in PAT to INR 8,595 Mn. EBITDA surged by 44.3%, reflecting improved operational efficiency. Significant growth was noted in both the Indian market and complex generics in the U.S. R&D investment reached INR 4,481 Mn, supporting ongoing innovation. The company remains a leader in multiple therapeutic areas with robust global presence.